ABOUT THE REPORT

As the world continues to grapple with the significant impact of the COVID-19 pandemic, there is an urgent need to develop an efficient, coordinated and sustainable model for a healthy and well-functioning vaccine research and development (R&D) ecosystem. “Powering Vaccine R&D: Opportunities for Transformation,” a new report published by the Sabin-Aspen Vaccine Science & Policy Group, uses lessons learned from the rapid development of COVID-19 vaccines to explore opportunities to overhaul vaccine R&D practices to better prepare for the next pandemic, to make strides against diseases currently without vaccines, and to establish next-generation vaccines that offer meaningful improvements.

View the report

ABOUT THE TOOLKIT

The following are sample and template materials to use to raise awareness about the report. Next to each image are sample social posts that you can use on your social media accounts.

Access the images
Timeframe for vaccine development

FACEBOOK/LINKEDIN

Vaccines don’t happen overnight. The development of a new vaccine typically takes years or even decades, though scientists responded to the COVID-19 pandemic in near-record speed. We can apply lessons from COVID-19 to speed up vaccine R&D for endemic diseases like malaria and for future pandemics. A new report from the Sabin-Aspen Vaccine Science & Policy Group examines the vaccine R&D process for several diseases, including COVID-19, and reveals five big ideas to make vaccine R&D more efficient. @AspenInstitute @SabinVaccine  

[insert URL]

TWITTER

Vaccines take decades to develop, but #COVID19 showed we can do it faster. New report by @sabinvaccine + @AspenInstitute offers lessons from #COVID and other diseases to speed up #vaccine R&D: [URL]
A new report published by the Sabin-Aspen Vaccine Science & Policy Group calls for restructuring vaccine the R&D ecosystem to meet the challenges of infectious diseases more effectively and efficiently. One of the biggest challenges vaccine R&D must solve: The current model of a “conductorless orchestra” doesn’t work. Vaccine R&D needs leaders to establish a transdisciplinary effort that gets all the players working together in harmony to advance vaccine science. Learn more in this new report by @sabinvaccine and @AspenInstitute.

[insert URL]
Vaccine R&D is a team sport. We can’t meet the threat of infectious diseases without collaboration between individuals across different disciplines, organizations, and governments. Plus, it requires a strong leadership structure that integrates the contributions of all players. A report published by the Sabin-Aspen Vaccine Science & Policy Group lays out a new framework and approach to vaccine R&D. @AspenInstitute @SabinVaccine

[insert URL]

Creating #vaccines for infectious diseases needs people across disciplines + strong leadership. Cutting-edge report from @sabinvaccine + @AspenInstitute calls for a new framework for vaccine R&D: [URL] #COVID
FACEBOOK/LINKEDIN

We must restructure vaccine R&D to accelerate the development of vaccines for infectious diseases we already recognize and for those yet to emerge. Lessons learned from COVID-19 show us how. Learn more in a new report from the Sabin-Aspen Vaccine Science & Policy Group. @AspenInstitute @SabinVaccine

(insert URL)

TWITTER

Faster, more efficient #vaccine R&D is possible. Lessons from #COVID19 show us how. Learn more from @sabinvaccine + @AspenInstitute’s new report: [URL] #COVID
The speed and success of the development of COVID-19 vaccines has many people wondering: Can the same innovation and transdisciplinary collaboration prevent the next influenza pandemic? Is the elusive search for a universal influenza vaccine coming closer to its end? A new report from The Sabin-Aspen Vaccine Science & Policy Group looks at stumbling blocks encountered by vaccine R&D and reimagines the post-COVID future. @AspenInstitute @SabinVaccine

To develop a universal flu vaccine, we need to reimagine #vaccine R&D using lessons from #COVID. Learn more from @sabinvaccine + @AspenInstitute’s new report: [URL]
Pandemics can be powerful stimuli for innovation. Following the 1918-19 flu pandemic, investments in infectious disease research led to vaccines for yellow fever, polio, measles, rubella, and hepatitis A and B. Following COVID-19, we’ll have a unique opportunity to establish new vaccine R&D norms that better prepare us to face the next pandemic. Read more in a new report by @sabinvaccine and @AspenInstitute.

[insert URL]

Pandemics can be powerful stimuli for innovation. A new report from @sabinvaccine + @AspenInstitute reveals ways to rethink vaccine R&D following COVID-19: [URL] #COVID
“Powering Vaccine R&D: Opportunities for Transformation” is a new report published by the Sabin-Aspen Vaccine Science & Policy Group that examines the core components of the vaccine ecosystem and finds opportunities to transform and accelerate the development of vaccines. The five Big Ideas presented in this report will help global health leaders meet the threat of infectious diseases more effectively and efficiently. Read the report here: [URL]
@AspenInstitute @SabinVaccine

"Powering Vaccine R&D: Opportunities for Transformation" is a new report from @sabinvaccine + @AspenInstitute that describes ways to accelerate development of vaccines: [URL]
#COVID